NIL-A misses primary end points in PD trial

Guilford (GLFD) said partner Amgen (AMGN) completed a Phase II study of their neuroimmunophilin ligand NIL-A in patients with mild to moderate Parkinson's disease (PD), and results suggest the 1000 mg...